NASACORT (triamcinolone (acétonide de))

• Key points

Favourable opinion for reimbursement in the indication extension for the treatment of symptoms of:

-    seasonal allergic rhinitis in children aged 2 to 5 years

-    perennial allergic rhinitis in children and adolescents aged 2 to 17 years.

• What therapeutic improvement?

No clinical added value.

• Role in the care pathway?

In case of allergy, the first measure to be implemented is avoidance of the allergen as far as possible, which can be difficult in the event of allergy to pollens. In children and adolescents, as in adults, the medicinal treatment of allergic rhinitis first involves oral or nasal antihistamines and cromones, then nasal corticosteroids.

In the 2016 ARIA recommendations, inhaled corticosteroid + oral or intranasal antihistamine combinations are proposed in patients with moderate to severe forms. However, the level of evidence for these recommendations is low. If these treatments fail, a short course of oral corticosteroids may be prescribed. In severe rhinitis not responding to corticosteroid therapy, allergen immunotherapy may be envisaged.

Role of the medicinal product in the care pathway:

NASACORT is an option following the failure of anti-H1 antihistamines in non-severe allergic rhinitis. It may be prescribed from the onset in the event of severe allergic rhinitis.

The lowest effective dose of nasal corticosteroids must be sought.